Member Info for JustHereForHemo

I like what you did there 121, very good!

So CBR has been spun out into a subsidiary of Hemogenyx called Bait Biotechnology and Prevail are actively seeking investments at Vlads presentations. Well allllllrighttyyyyy then :-P

I suggest people listen right to the very end... See who speaks up and what they say... ;-)

Brain Cancer! Finally we know!

Ok... Added a TEENY bit more, just restating whats been posted already by many.

Some traders who were holding for trials have sold (RNS makes it clear this is PROBABLY 1mth+ away) so the traders will sell, ignore possibility of any other updates and aim to return IMO end of October.

Some Investors will have sold for fear of dilution/placing, no guarantee it wont happen but IMO WORST case scenario is a few mil at a discount of 10-15% on previous day closing at some point in the future following a bit of a pump/positive update when SP is significantly higher than today. BEST case scenario, Vlad has discovered the joy of institutional investment, he has started to win people over and will raise cash as required to get to trials at either a premium or market price and not go near the market. Prevail being the obvious choice, if they injected more cash that would remove this attack vector and secure their initial investment.

Either way selling today because there may be a placing at some point in the future at an unknown SP is just stupid, thats pretty much every small cap on the market, everyone needs to raise and unless you know when and what terms your gambling! Lets not forget the 4m raise was done at 2.5p at the start of the year when SP touched 4p having been around 1.5p for months before. If you were told when SP was 1.5p there is going to be a placing in a month would you have sold? What if you were told its going to happen after a significant rise to 4p with a placing at 2.5p? What would you do then? because thats the situation, you can be worried about a future placing, but every chance it wont be a public placing, it wont be at a discount to today and very likely to be after CH lifted, but we dont know so its all a gamble. Buy/sell/hold, gl whatever you do

Anyway, done posting for the day, I got my shares at 2p which was a massive surprise, the traders who expected an update in days have dumped their load and probably piled into VAST or something.

Been here this long I am not about to sell just because I still have to wait another few weeks or months. Looks like I am not alone, plenty of buying down here, cant see it finishing blue but would not be surprised to see 2.15-2.2 again before we close.

I am not sure why the confusion here? Micky the issue people have with your posts was that you state things as FACT, use words such as MAY instead of WILL or "I THINK" instead of "I KNOW". If you were so certain of being right and were right each time you would be a very rich man. Words matter and unless your inside your guessing like the rest of us but trying to pass it off as fact.

Sponge as for the gap, I did not pass comment but I think HH did? And from memory he simply pointed out there were lots of gaps, most of them to the upside and they are just as likely to be filled as that 1.8p one, selectively picking the only gap on the downside is disingenuous and misleading, are you saying that only ever downside gaps get filled?

As for this market reaction?

IMO NOT a huge over-reaction, its the first formal indication I have seen that they still have any work remaining, before today the window for starting trials was any time from NOW until end of the year. Some traders I speak too had the same uncertainty, not willing to sell because they could miss the rise. The update today, IMO if I am being honest PROBABLY gives traders 1 month when its unlikely trials will start, there is every chance of other updates in that window but nothing that jumps out as imminent. But then again Prevail was completely unexpected too. But bottom line is Traders who only care about CAR-T trials will take today as a trigger to sell and come back in a few weeks, so a 10-12% drop for that reason is fair and understandable. Those willing to wait it out have the opportunity to add, thats how the market works. I was one of those who decided to add.

Micky reported to FCA for insider knowledge.

The issue was never that you predicted it would go below 2p, the issue is, was and will always be when you try and paint it as FACT with nothing to back it up. IF you had inside knowledge that IND was STILL not ready and that would lead to this sell off then you were posting insider knowledge and thats illegal, if you dont want abuse over your posts stop stating it as fact. The update today could just as easily have said all the steps had been complete and they are awaiting final confirmation before starting trials.

The Company successfully raised £4,056,250 (before expenses) through the allotment and issue of 162,250,000 new ordinary shares at 2.5 pence per share during the period to 30 June 2023 and a further $830,000 (£668,000) through the allotment and issue of 11,066,667 Ordinary Shares, after the period end. These proceeds were raised in order to facilitate the progression of the Company's HEMO-CAR-T product candidate into clinical trials and to enable the Company to continue development of product candidates for the treatment of viral infections based on its CBR platform.

Substantial funding will be required by the Company during the clinical trial phase and further funding will be sought by the Company prior to the commencement of the Phase I clinical trials.

At 20m mCap(roughly where it is now) "Substantial Funding" for me does not suggest 1-3m here and there. The market IMO is closed in terms of raising anything even remotely close what is required whilst the SP is down here and any suggestion that Vlad can fund clinical trials based on highly dilutive placings is just pie in the sky. Even the last RNS with the initial investment of 1% @6p, that was just enough to get the CMO started. IMO thats the goal for Vlad, raised just enough to get the CH lifted, they have enough for a few months and considering they said "Start trials in 2023" thats good enough.

I have bought another 100k in the dip, IMO it will be seen as too good an oppertunity by many to miss, yes the RNS was not fantastic, but it gives very clear indications that good times are not that far away.

Anyway, obviously I cannot say that Vlad WONT raise in a public placing before getting to that point, only that I believe he wont need to and given how successful he was with Prevail he will once again look to institutional investment at a premium. But time will tell.

Yes very likely, they will have to raise cash at some point, but the premium raise at 6p imo was enough to get to that point, Get into clinical status and raise away. With 3m in bank hardly any urgency.

The trolls will attack the expenditure, £4.3m out £4.7m raised, that is pretty much the only thing that whilst not negative as they have balanced the sheets remains the only tool trolls can reach to. £3m cash as of end of June, before they raised the £668k at 6p, so financially speaking? Not a hugely great balance sheet, but certainly more than enough to see the company into trials.

CBR + CDX sound like still extremely promising but waiting for CAR-T to move clinical

On CAR-T:

"While the placing of HEMO-CAR-T on clinical hold was a setback, we are clear on the particular area in which additional information is required, and we are encouraged by the FDA's response to our plans to resolve the issues. We remain confident and committed to progressing HEMO CAR-T to clinical trials as the Company's next step. We have put measures in place to allow us to achieve this milestone, including the new agreement with Prevail InfoWorks and the investment by Prevail Partners, which gives a clear signal of the project's value even at this pre-clinical phase. Meanwhile, the prospects for our other cutting-edge assets continue to be positive, and CBR in particular is beginning to attract real attention."

Basically says its not finished, they are not going to start trials tomorrow HOWEVER the entire tone is factual, optimistic and removes doubt about it actually happening in the near future.

Overall? No shockers, nothing eye popping great, nothing bad or negative, a fairly beige update but enough to give existing holders confidence.

It came early for once! Well done Vlad :-)

Feel free to put forward your opinion, IMO the CMO signed the master agreement only after they had had a chance to review the plan put forward by Hemogenyx and they were satisfied that it was as good as done. Previously Vlad stated they would only sign this master agreement AFTER IND approval so that is a strong indicator. In addition the submission to the FDA contained lab results, not certified by a 3rd party but still results proving they had taken the physical steps required to clear the hurdle and provisionally the FDA were happy, what comes next in my opinion is the tidy up, preparing GMP documentation, external certification etc, time consuming but low risk. Finally the statement in the RNS which is regulated stated they intend to start trials in 2023, its not guaranteed HOWEVER they have to make that statement in good faith.

The above is the basis for my optimism, all founded in referenceable sources and no great leaps of faith required.

Stu, I have always been consistent on this and if you go back years on my posts I have always been clear with MY plan, and thats to derisk before clinical trial results are out, not because I dont believe it will be successful, but because its not guaranteed. And whilst I am happy to say I believe there is a relatively safe and massive potential now to invest before trials start I will never say the trials are guaranteed and people should risk everything on their success. Going clinical is a huge milestone and I genuinely believe getting IND approval and LAUNCHING the trials will be a massive boost to the SP, MOST companies never get to that point, I think its the biggest failure rate, we have pretty much de-risked that with the FDA letter of approval for the IND plan but for anyone to suggest that Phase 1 is almost certain to be successful is irresponsible and wrong. I believe it will be successful, I will be holding alot of shares on that belief but I do so knowing the failure rate in trials is still high.

What crack are you smoking today? How much more balanced can you get? NOBODY here is saying anything about Hemogenyx is guaranteed, everyone accepts risk and there is plenty of balanced debate on WHAT that level of risk is and at what point in the timeline that risk comes in.

All you do is post irrelevant links that have zero relevance to Hemogenyx trying to inject some FUD, do you see me attacking Stu who is currently in a pretty negative mood? No! And why? Because the science of the trials to date is not great, its relevant to Hemogenyx and as such I and others respond to him. You on the other hand just use ChatGPT to generate some BS and post whatever unrelated links you find or try and cross ramp to some other share your invested in.

@stu https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216020/

Probably does more to support your argument and thats fine, I will never argue against the science, CAR-T for AML is the holy grail which has yet to be found/proven. Vlad is bullish that HEMO-CAR-T will be it and only time will tell if he is correct but yes, to date everything else has failed. Bad for patients, but does present an opportunity for Hemogenyx, as they are running a race to commercialisation, but being small they are slow, however the forerunners have been dropping out like flies.

Will HEMO-CAR-T be the winner? I hope so, but its a long way to go.

What is clear however that those forerunners which have dropped out, such as linked by Vlad, ALL were picked up and sponsored very early by big pharma. None of these CAR-T treatments are making it to phase 3 before licencing.

I still think Vlad will hold out until trials start which IS a huge gamble, as you say the risk factor here is greater, HOWEVER because the market IS so thin, there is so few treatments and the competition is dropping like flies, the pay off here if it works could be absolutely huge. I would be much more worried if there were dozens of CAR-T for AML trials in phase 2 and 3 already, chances of penetrating a saturated market as a small company or achieving fast track designation would be next to none.

Clinical trials are risky.

Its not 60% going to pass Phase 1/2a, its either going to pass or its going to fail, and plenty have failed.

As I have said many times in the past, even I will be de-risking slightly BEFORE results come out for clinical trials as nothing is guaranteed.

HOWEVER Being a Clinical Oncology target CAR-T pharama will demand a much higher mCap and SP so slicing just as trials start will give a very handsome return. After that? Sitting on a free ride into trials is a risk I am happy to accept

Tweet from Vlad:

"It is sad that anti-CD47 antibodies do not show efficacy in AML patients. AML patients need new treatment and new hope. It seems that the $4.9B purchase of Fourty Seven by Gilead was a mistake......

https://t.co/E3I4YMXvOX"

I will take "what is FLT3/FLK2?" For $500 please Bob!

121.... Great find, ty EFM for posting.....

So Eli Lilly now own 1% of Hemogenyx, are running their CAR-T human trials and have a stake in CDX though milestone payments and are possibly the pharma in licencing talks there?

That relationship is getting very cosy indeed.